Bicycle Therapeutics Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

NasdaqGS:BCYC Recent Insider Transactions by Companies or Individuals
Date	Value	Name	Entity	Shares	Max Price
06 Apr 26	SellUS$11,877	Michael Skynner	Individual	2,404	US$5.05
06 Apr 26	SellUS$8,736	Michael Hannay	Individual	1,772	US$5.05
06 Apr 26	SellUS$4,438	Travis Thompson	Individual	901	US$5.05
06 Apr 26	SellUS$37,964	Kevin Lee	Individual	7,683	US$5.05
05 Jan 26	SellUS$38,206	Alethia Young	Individual	5,745	US$6.80
05 Jan 26	SellUS$141,199	Kevin Lee	Individual	21,314	US$6.80
05 Jan 26	SellUS$34,491	Michael Hannay	Individual	5,194	US$6.80
05 Jan 26	SellUS$44,127	Alistair Milnes	Individual	6,660	US$6.80
05 Jan 26	SellUS$41,804	Michael Skynner	Individual	6,311	US$6.80
05 Jan 26	SellUS$16,147	Travis Thompson	Individual	2,432	US$6.80
03 Oct 25	SellUS$17,860	Alistair Milnes	Individual	2,125	US$8.41
03 Oct 25	SellUS$2,723	Travis Thompson	Individual	324	US$8.41
03 Oct 25	SellUS$15,147	Michael Skynner	Individual	1,802	US$8.41
03 Oct 25	SellUS$46,182	Kevin Lee	Individual	5,494	US$8.41
03 Oct 25	SellUS$6,076	Michael Hannay	Individual	723	US$8.41
02 Oct 25	SellUS$1,823	Alethia Young	Individual	217	US$8.40

Insider Trading Volume

Insider Buying: BCYC insiders have only sold shares in the past 3 months.

Ownership Breakdown

What is the ownership structure of BCYC?
Owner Type	Number of Shares	Ownership Percentage
State or Government	61,153	0.0877%
Individual Insiders	1,256,670	1.8%
General Public	10,665,585	15.3%
Institutions	27,367,517	39.3%
Hedge Funds	30,356,101	43.5%

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Top Shareholders

Top 25 shareholders own 78.41% of the company

Ownership	Name	Shares	Current Value	Change %	Portfolio %
43.6%	Baker Bros. Advisors LP	30,356,101	US$146.9m	0.11%	0.77%
4.98%	Forbion Capital Partners B.V.	3,468,430	US$16.8m	0.47%	2.45%
4.64%	Armistice Capital LLC	3,236,000	US$15.7m	8.66%	0.37%
4.52%	Artal Group S.A.	3,149,049	US$15.2m	56.5%	0.29%
2.4%	Acadian Asset Management LLC	1,671,258	US$8.1m	27.1%	0.01%
2.34%	Long Focus Capital Management LLC	1,633,091	US$7.9m	15.1%	0.39%
2.19%	GSK Equity Investments, Limited	1,529,561	US$7.4m	0%	0.65%
1.71%	Candriam, Société En Commandite Par Actions	1,192,279	US$5.8m	1.7%	0.01%
1.68%	T. Rowe Price Group, Inc.	1,171,787	US$5.7m	-15.4%	no data
1.65%	Principal Global Investors, LLC	1,148,272	US$5.6m	-0.01%	no data
0.86%	Kevin Lee	598,811	US$2.9m	5.17%	no data
0.84%	Schroder Investment Management Limited	584,770	US$2.8m	0%	no data
0.82%	BNPP Asset Management Holding	568,225	US$2.8m	0%	no data
0.81%	Renaissance Technologies LLC	566,600	US$2.7m	9.23%	no data
0.68%	Silvercrest Asset Management Group LLC	476,976	US$2.3m	0%	0.01%
0.67%	Morgan Stanley	465,222	US$2.3m	-43.5%	no data
0.66%	Birchview Capital, LP	462,700	US$2.2m	200%	1.19%
0.55%	Medical Strategy GmbH	386,795	US$1.9m	0%	0.12%
0.48%	BlackRock, Inc.	332,889	US$1.6m	17.9%	no data
0.47%	Millennium Management LLC	326,626	US$1.6m	-69%	no data
0.43%	Jefferies Financial Group Inc.	297,247	US$1.4m	-26%	0.01%
0.39%	Moore Capital Management, LP	275,000	US$1.3m	120%	0.03%
0.39%	Citadel Advisors LLC	271,383	US$1.3m	43.6%	no data
0.38%	Bessemer Investment Management LLC	265,973	US$1.3m	25.3%	no data
0.32%	Palo Alto Investors LP	221,071	US$1.1m	0%	0.15%

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2026/04/27 18:08
End of Day Share Price	2026/04/24 00:00
Earnings	2025/12/31
Annual Earnings	2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Bicycle Therapeutics plc is covered by 22 analysts. 12 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Kalpit Patel	B. Riley Securities, Inc.
Arlinda Lee	Canaccord Genuity
Li Wang Watsek	Cantor Fitzgerald & Co.